Proton Pompa İnhibitörlerinin Uzun Dönem Kullanımındaki Etkileri

Yıl 2020, Cilt: 15 Sayı: 3, 76 - 81, 16.10.2020

Murat İspiroğlu , Kadir Gişi , Bülent Kantarçeken

https://doi.org/10.17517/ksutfd.690248

Öz

Proton pompa inhibitörleri (PPI) iyi bir güvenlik profiline sahip ve toplumda çok sık kullanılan ajanlardır. Sık kullanılan bu ilaçların yan etkisi konusunda net veriler olmamakla birlikte, bu yan etkilerin daha çok uzun süre kullanımı sonucu baskılanan mide asidine bağlı olduğu düşünülmektedir. Biz burada daha çok zeminde oluşan uzamış hipoklorhidri ve hipergastrineminin neoplastik sonuçları, malabsorbsiyon, enfeksiyonlar ve diğer nedenler ana başlıkları altında konuyu tartışmaya çalıştık.

Anahtar Kelimeler

Proton pompa inhibitörleri, Yan etkiler

Destekleyen Kurum

yok

Proje Numarası

yok

Kaynakça

• 1. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500.
• 2. Laine L, Ahnen D, McClain C, et al. Potential gastrointestinal effect of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-68.
• 3. Katz P, Gerson L, Vela, M. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-328.
• 4. Search PPIs at :http://www.fda.gov/Drugs/DrugSafety/default.htm.
• 5. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37–47.
• 6. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996:18;334:1018-22.
• 7. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
• 8. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Alim Pharmacol Ther 2006; 24: 1341-8.
• 9. Blanchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasiais common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008;6:180-5.
• 10. Hongo M1, Fujimoto K; Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010 Jun;45(6):618-24.
• 11. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
• 12. Jianu CS, Lange OS, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitör. Scand J Gastroenterol 2012:47:64-7.
• 13. Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012;36:644-9.
• 14. Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med. 2013 Aug;16(8):449-58.
• 15. Thjobleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 and 20 mg rabebrazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003;17:343-51.
• 16. Kupier EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid supressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
• 17. Lundell L, Matinen P, Myrvold HE, et al. Nordic GERD Study Group: Lack of effect of acid supression therapy on gastric atrophy. Gastroenterology 1999;117:319-26.
• 18. Malfertheiner P, Megraud F, O'Morain CA, et al, European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
• 19. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
• 20. Watson SA, Smith AM. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001;61(2):625-31.
• 21. Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectalcancer: a prospective study. Gastroenterology 1998;115(2):275-80.
• 22. van Soest EM1, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008 Apr;103(4):966-73. Epub 2007 Dec 5.
• 23. Robertson DJ1, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007Sep;133(3):755-60.
• 24. Yang YX1, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007 Sep;133(3):748-54. Epub 2007 Jun 20.
• 25. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047.
• 26. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001.
• 27. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107(7):1011-9.
• 28. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Eng J Med 2011;365:1693-703.
• 29. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-supppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA 2005;294:2989-95.
• 30. Merli M, Lucidi C, De Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2014 May 17. doi: 10.1111/liv.12593.
• 31. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). (http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm (Accessed on February 08, 2012).
• 32. Johnstone J, Nerenberg K, Loeb M, et al. Meta analysis: proton pump use and the risk for community aquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-77.
• 33. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310.
• 34. Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013; 28:223.
• 35. Sarkar M, Hennesy S, Yang YX, et al. Proton pump inhibitor use and the risk for community aquired pneumonia. Ann Intern Med 2008;149:391-8.
• 36. Estborn L, Joelsen S. Occurrence of community aquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31:627-36.
• 37. Sultan N, Nazreno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and metaanalysis of clinical trials. Can J Gastroenterol 2008;22:761-6.
• 38. Mullin MJ, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008:28:1317-25.
• 39. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitör therapy and risk of hip fracture. JAMA 2006;296:2947-53.
• 40. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138:896.
• 41. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361.
• 42. Targownick LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis related fractures. CMAJ 2008; 179: 319-26.
• 43. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonist are associated with hip fractures among at risk patients. Gastroenterology 2010; 139: 93-101.
• 44. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. FDA. March 28, 2011. www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm.
• 45. Proton pump inhibitors: risk of bone fractures. Health Canada. April 4, 2013. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php. Accessed August 27, 2013.
• 46. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.
• 47. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump in hibitors. Clin Endocrinol (Oxf) 2008;69(2): 338-41.
• 48. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36(5):405-13.
• 49. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). FDA. March 14, 2011. www.fda.gov/drugs/drugsafety/ucm245011.htm. Accessed June 11, 2013.
• 50. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36:405-413.
• 51. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57(4): 422-8.
• 52. Heidelbaugh JJ, Metz DC, Yang YX. Proton Pump Inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 2012;66:582-91.
• 53. Dharmarajan TS1, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008 Mar;9(3):162.
• 54. Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther 2012; 19:185-9.
• 55. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007;56(9):1291-5.
• 56. Veress B, Lofberg R, Bergman L. Microscopic colitis syndrome. Gut 1995;36:880-6.
• 57. Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. J Clin Gsatroenterol 2009:43;551-3.
• 58. Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8.
• 59. Keszthelyi D1, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010 Nov;32(9):1124-8.
• 60.Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128:845.
• 61.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm (Accessed on November 18, 2009).